{"name":"Verastem Oncology","slug":"verastem","ticker":"VSTM","exchange":"NASDAQ","domain":"verastem.com","description":"Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.","hq":"Needham, MA","founded":0,"employees":"102","ceo":"Dan Paterson","sector":"Oncology","stockPrice":5.55,"stockChange":0.1,"stockChangePercent":1.83,"marketCap":"$487M","metrics":{"revenue":30914000,"revenueGrowth":0,"grossMargin":85.1,"rdSpend":0,"netIncome":-209471008,"cash":204990000,"dividendYield":0,"peRatio":-4.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Duvelisib patent cliff ($100M at risk)","drug":"Duvelisib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Verastem Oncology reported its fourth quarter and full year 2023 financial results, with a net loss of $43.1 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Verastem Oncology Announces Exclusive Licensing Agreement with BeiGene for Duvelisib in China","summary":"Verastem Oncology entered into an exclusive licensing agreement with BeiGene for the development and commercialization of duvelisib in China.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPazhHcEtJa1hEQjNGZGRZcG5MaXZQUDZFMTIyTkhCd3NOS3Vuei0tdEZJS0V5OVIxY2Z4bld6TE85MEwwaGNhNEV5bWR4d2JMaXdleDJfeXFJdUR0aF90YjVRRkVLMy1CMnVsblQyZFhJRnlSWFZxUEcya0pOc2xVcEpfNlB1UWtSR0RsZzhSc1hpV0Z1WC02cVMtdlhCazFCLUU2MVZNT1NISTlCX0VhUTA4RXZjZDdNQUdTUm5WVW5fWExxdDBN?oc=5","date":"2026-02-27","type":"pipeline","source":"AD HOC NEWS","summary":"Verastem (VSTM): Can This Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS","headline":"Verastem (VSTM): Can This Beaten-Down Biotech Still Surprise Wall Street?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQSl9OVEVSc204TzB5MmpoU29IV1pJOUNVNXptdlFHWVQzQS11QWJVdlNjNThtMEtLc3Q0TlllSlNCbzNLTlUzX2s4dnN1eHlCdHo3SXZBYnE0OGwwT1QtWEVsTEJNUjJjQ1dUTXR2RTh1bVhTT2wwN3o5VWtnQ0swRkh3Nnp1SWZaVmpEUU5OY1RUUi1Xbnc3Yk5IcDRqTzJYTzZxQ296QTBid0FtSGhjTEhaalFVeWxy?oc=5","date":"2026-02-04","type":"pipeline","source":"Stock Titan","summary":"Cancer drugmaker turns to KRAS pill after $30.9M launch year - Stock Titan","headline":"Cancer drugmaker turns to KRAS pill after $30.9M launch year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPcS1TMVgydE5ZeDFDdWF1RlJ1d0J6WW9Pa3Bla3FlQXZRY3lxc1RuTWJ3b0JJY3hza0hTbW5GQnlLWlh2bG0zclVTRkVELUt2czY2N0hpdVg4bzlDLTNrY3lIeWNHbktsNXVfZ1ZZUE5WdmNDakYtUWk2UmdHclUtaXpsMjIxeGx0VVUxbWVFNkNSRjZtTXlkMzBpRWF1TWJISzNqQzJtckZEZk1pcFM0SHc1enRoZDFh?oc=5","date":"2025-12-31","type":"pipeline","source":"The Pharma Letter","summary":"Verastem to discontinue Avmapki/Fakzynja combo in KRAS G12C-mutated NSCLC - The Pharma Letter","headline":"Verastem to discontinue Avmapki/Fakzynja combo in KRAS G12C-mutated NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNQ2lDd2gtaGplaGRUXzRSNllBRGF0dXRFSHJUaktRczh0SzVKaVI2bE5CcXM4c1Znc1ktdGRHZFljNHFWUWVEMXBpWW9qLWw2ajRMU0k5RlZ5OTBpTnBKYk5iajlYUmJYZU43ajBDVDRaQWxHMmx1TkVSdUlYZ0pIdjhtMkZmYnFpM0ZobG4yWUxPbEtxV0t2dlhwQVJKNEN5dk1MeEtWRzE4VlNGZjg4RXppTTZLLXJ5UlRhTFVyWmhIMTJlS1N2aVlqWkFkSG1yOFE4dTFSZ2hvT0FsX1E?oc=5","date":"2025-12-15","type":"trial","source":"Business Wire","summary":"Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth - Business Wire","headline":"Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxOajYzVzZPMS0td0RiMGRFRTdKWEgtQzhFQ2FaV20tY3RDeGN2cmVmaE82MUwyVEtmVmQ2MGxINkpIQk4xYzBLdjlIWTJZSE52cXpneUgxUE5XNGoyaHp2U2JzblpJV1pJN0ppRk9FNXlNZEZSVjFyOElTN1JkOGtwazFyLU5Pcms1Y3RTZjd5YWpQck54OG90TktEZ3dIMHRRMDlmY18tY2tfblhXcjdxMlFJV21SVUN0Rl9RbGUzZG9NRXlvVTNoY3BEaWNISmR3V044M0hpOXdJUUtYTjBEVGZ1ai1yRGdWUG5aLWk0M2tvOF94akJwUA?oc=5","date":"2025-11-13","type":"pipeline","source":"Business Wire","summary":"Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants - Business Wire","headline":"Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOUDVoQW1ZT2cyY3BjczZ1dXN6REZSemlQbkU3aXdVRWZROTBCZ1diTnkwQUJTaWhUdmZnM1plWEdkNFFnY3NXS3RpM2tkLVd5bjM2TFF3eTJWdV9GOEdkaGNxRGI4dUhvMDA1SERwLVl1QjJ1Ylc3MF85Y1g1cHpYMDM1eVVhcVZMVENuRWJn?oc=5","date":"2025-07-16","type":"pipeline","source":"Seeking Alpha","summary":"Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha","headline":"Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHZIb040TnlHNmp0Y2ZDNVl4UU94bUZORE5KSGItREhsajdNdUUxUnZveTZKSUlBaHlzVVZPazI3c2k5SU1EWFFGNHh3RHF4aU5UTUlNb1Q4NUxGQ2pVUU5KQmlPR2tYQnp2T2hTZDBOU0VXeEp5WHVubUE0aW4wYXh0YzFwQlAtZWNOX09RUjhoMWh0bGc3NXFrX0gxaUJDRURicUh5bThUbXlPNFdaSUM5UTlXblU5Q2tzR2FxRno?oc=5","date":"2025-05-08","type":"regulatory","source":"MedCity News","summary":"Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer - MedCity News","headline":"Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQRk0yd3pOclRickg0NkhpYl90Q3c0SThxUFlNSS1TcjBhS011NkN3UXVRX0M3Z3RTa0NHd2VjVzl6d19Eck1RdlhjQkk0RHIxTmFVOHhFV1k5YTNZcE1zbldrSkhNaUoxQVoyb0Ywck01SjJ1VUhZak9hN2MzakR4Y2VNQUNoVEVZMTc1NUl6OUxCRS1qS1QxRFRvc1FoU1BlTXdDaWpmX2ltc3phdlNpUF93?oc=5","date":"2025-05-08","type":"regulatory","source":"Reuters","summary":"US FDA approves Verastem's ovarian cancer therapy - Reuters","headline":"US FDA approves Verastem's ovarian cancer therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxOelpiVGthREJxY25ibmJ1Wkx4T2tHbkJ2QmM1Q1lkTm05T0VuZmk5N1c0OEtiZDZ5TUZYdnBDdG9pSzQwSDZUZ1FrRXZrWEdESTNKYmVvNmJEVVEyS0dUYUVCZlBQVG9PdGhhSzRMZk1MSHJjUlpzM0pWcklELXoxNGFFdllBOGVaS3dTQmd6Rm5hUzVaYVVDV1RFNXZ4QjhRWGNzbXV0b29FX2stRFFLSnVkRVdHOFpnSGVIQmVJNEJQS1JxTVBaZEdoNGR0dlExelh4U1dmMzJOejhTMHJnRWo2bHE5c2htbVRCVUlEcGlGOWFOOTZYeFN1X0wzeFc5TkM0?oc=5","date":"2025-03-20","type":"earnings","source":"Business Wire","summary":"Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates - Business Wire","headline":"Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBybUUyeTJWTURkNG5XRjctd0k1bjdCeEtBUXhBQ1ZlY3F6R2ZrTzhvX0Q0XzF3M2R2QmQ0SW5TN21FZkNlTU5EV28zVzBzSTVaRTlwZGozUTNNY1JkelJyOVZaaWwtNW45OF9DcGdyWXl1X1AxYzExY3o2eVJhZzA?oc=5","date":"2025-01-15","type":"pipeline","source":"The Pharma Letter","summary":"Verastem Oncology names Matthew Ros as COO - The Pharma Letter","headline":"Verastem Oncology names Matthew Ros as COO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNTWhLWVZ3MHllZGpudkZlaV94TzNFNlZVZ0VIcl9kUHd4Y0g4VlRKSjhPSEN3dTIxdHpHaWpBT1JXYW9HSWhET01lRE5JMWR2V0pJQldheF9aQUdmWkpIRFFrQTZySHVRdU5GRU9TYU9BUlRLbUxySUtMLVZLcm5BRFFXMmJGa1VtUHhnRjJhMA?oc=5","date":"2025-01-02","type":"regulatory","source":"The Pharma Letter","summary":"Verastem soars on FDA priority review for avutometinib - The Pharma Letter","headline":"Verastem soars on FDA priority review for avutometinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPVFRXZVVoMUNja21qQVNoX2ZCRV9MOUNLeWwteDd0Ym1fQmlVbzBZeUFhUE1mbWxfYU5pZjMzaXlNd21EaTgtS0FyUlpXYW90bDczYjRhZzU0SUUxOTV5bUpPdGRmMldYMjJDaHhjRjQwa21LcnpTZFhZYmk5aVRqMVFsZmFGNnVwVWhpSVF6LVViUXZYcUVMWFF1YkVqa0NhejllZw?oc=5","date":"2024-06-10","type":"deal","source":"Seeking Alpha","summary":"Verastem: Market Overreaction Creates A Dip Buying Opportunity (NASDAQ:VSTM) - Seeking Alpha","headline":"Verastem: Market Overreaction Creates A Dip Buying Opportunity (NASDAQ:VSTM)","sentiment":"neutral"}],"patents":[{"drugName":"Duvelisib","drugSlug":"duvelisib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Gilead Sciences","Bristol-Myers Squibb","Roche Holding"],"therapeuticFocus":["Hematologic Malignancies","Solid Tumors"],"financials":null,"yahoo":{"currentPrice":5.55,"previousClose":5.45,"fiftyTwoWeekHigh":11.25,"fiftyTwoWeekLow":4.01,"fiftyTwoWeekRange":"4.01 - 11.25","fiftyDayAverage":5.89,"twoHundredDayAverage":7.38,"beta":0.43,"enterpriseValue":360880320,"forwardPE":-4.7,"priceToBook":7.54,"priceToSales":15.77,"enterpriseToRevenue":11.67,"enterpriseToEbitda":-2.13,"pegRatio":0,"ebitda":-169400992,"ebitdaMargin":0,"freeCashflow":-82332872,"operatingCashflow":-137508992,"totalDebt":87169000,"debtToEquity":152.4,"currentRatio":3.09,"returnOnAssets":-61.1,"returnOnEquity":-1480.2,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":8,"targetMeanPrice":16.38,"targetHighPrice":19,"targetLowPrice":14,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.8,"institutionHeldPercent":87.6,"sharesOutstanding":87835106,"floatShares":75061247,"sharesShort":17851179,"shortRatio":11.45,"shortPercentOfFloat":20.3,"epsTrailing":-3,"epsForward":-1.18,"revenuePerShare":0.45,"bookValue":0.74,"officers":[{"age":64,"name":"Mr. Daniel W. Paterson","title":"President, CEO & Director"},{"age":37,"name":"Mr. Daniel  Calkins","title":"Chief Financial Officer"},{"age":62,"name":"Dr. Michael Glen Kauffman M.D., Ph.D.","title":"President of Development & Director"},{"age":null,"name":"Dr. Robert A. Weinberg Ph.D.","title":"Co-Founder & Chair of Scientific Advisory Board"},{"age":49,"name":"Dr. Michelle  Detwiler M.D., Ph.D.","title":"Co-Founder"},{"age":67,"name":"Dr. Jonathan  Pachter Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Ms. Julissa  Viana","title":"Vice President of Corporate Communications & Investor Relations"},{"age":null,"name":"Mr. Mark J. Wanda","title":"Senior VP of Legal & Chief Compliance Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.verastem.com","phone":"781 292 4200"}}